Related references
Note: Only part of the references are listed.Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group
Miriam Mendez et al.
HEMATOLOGICAL ONCOLOGY (2019)
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study
Ian W. Flinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
John P. Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy
Shigeru Kusumoto et al.
BLOOD (2019)
The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies
Jane E. Norman et al.
BONE MARROW TRANSPLANTATION (2019)
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
Anas Younes et al.
LANCET HAEMATOLOGY (2019)
Novel agents for relapsed and refractory follicular lymphoma
Chan Yoon Cheah et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
Ajay K. Gopal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Response rate to lenalidomide plus rituximab (R-2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.
David Andorsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
F. Morschhauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
Judith Trotman et al.
LANCET ONCOLOGY (2018)
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Nancy L. Bartlett et al.
BLOOD (2018)
Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations
Koorosh Korfi et al.
EPIGENETICS (2017)
DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
P. Zinzani et al.
HEMATOLOGICAL ONCOLOGY (2017)
OUTCOME OF CURATIVE RADIOTHERAPY FOR LOCALISED FOLLICULAR LYMPHOMA IN THE ERA OF 18 F-FDG PET-CT STAGING: AN INTERNATIONAL COLLABORATIVE STUDY ON BEHALF OF ILROG
J.L. Brady et al.
HEMATOLOGICAL ONCOLOGY (2017)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
R. Marcus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Lenalidomide Maintenance after R-CHOP Therapy in Diffuse Large B-Cell Lymphoma: Can It Be a Standard of Care?
Reyad Dada
ACTA HAEMATOLOGICA (2017)
Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study.
Loretta J. Nastoupil et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Activity of the immunologic doublet of lenalidomide plus obinutuzumab in relapsed follicular lymphoma: Results of a phase I/II study.
Nathan Hale Fowler et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M. Dreyling et al.
ANNALS OF ONCOLOGY (2017)
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.
Mathias J. Rummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT
S. P. Robinson et al.
ANNALS OF ONCOLOGY (2016)
Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial
Clementine Sarkozy et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
Laurie H. Sehn et al.
LANCET ONCOLOGY (2016)
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Carla Casulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)
John P. Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
Alessandro Pastore et al.
LANCET ONCOLOGY (2015)
Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study
H. R. Junlen et al.
LEUKEMIA (2015)
90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease
Felipe Samaniego et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Rituximab Extended Schedule or Re-Treatment Trial for Low-Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402
Brad S. Kahl et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non- inferiority trial
Peter J. Hoskin et al.
LANCET ONCOLOGY (2014)
Rituximab versus a watch-and-wait approach in patients with advanced- stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
Kirit M. Ardeshna et al.
LANCET ONCOLOGY (2014)
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices
A. K. Nooka et al.
ANNALS OF ONCOLOGY (2013)
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience
Daryl Tan et al.
BLOOD (2013)
Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I
Sylvain Fouliard et al.
EUROPEAN JOURNAL OF CANCER (2013)
Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016
Oliver W. Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi
Massimo Federico et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Incidence, risk factors and outcome of histological transformation in follicular lymphoma
Annarita Conconi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Autologous Stem Cell Transplantation in Follicular Lymphoma: a Systematic Review and Meta-analysis
Murtadha Al Khabori et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study
Nathan Fowler et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles et al.
LANCET (2011)
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin et al.
NATURE (2011)
Prognostic Factors in Follicular Lymphoma
Thomas Relander et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years
Emmanuel Gyan et al.
BLOOD (2009)
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
Massimo Federico et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Personal use of hair dye and the risk of certain subtypes of non-Hodgkin lymphoma
Yawei Zhang et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2008)
Impact of [18F] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma
Andrew Wirth et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Frequency of BCL2 and BCL6 translocations in follicular lymphoma: Relation with histological and clinical features
Andrea Diaz-Alderete et al.
LEUKEMIA & LYMPHOMA (2008)
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
Roswitha Forstpointner et al.
BLOOD (2006)
Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy
BA Guadagnolo et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Smoking and non-Hodgkin lymphoma: Case-control study in Italy
R Talamini et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS
E Deconinck et al.
BLOOD (2005)
Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy
R Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group
G Lenz et al.
BLOOD (2004)
Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial
KM Ardeshna et al.
LANCET (2003)
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma
JF Seymour et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
High-dose, therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial
HC Schouten et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
